US2011044955A1PendingUtilityA1

Altering memory by affecting staufen

60
Assignee: TULLY TIMOTHY PPriority: Jun 25, 2002Filed: Nov 20, 2009Published: Feb 24, 2011
Est. expiryJun 25, 2022(expired)· nominal 20-yr term from priority
Inventors:Timothy P. TullyRoderick E. M. ScottRusiko Bourtchouladze
G01N 33/5035A61P 25/28G01N 33/6896G01N 33/502G01N 2500/00G01N 33/5008G01N 33/5088A61P 25/00G01N 33/5058G01N 33/5023
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides cell-based screening methods for identifying pharmaceutical agents which are capable of modulating (have the ability to modulate) STAUFEN function by screening for STAUFEN function.

Claims

exact text as granted — not AI-modified
1 - 27 . (canceled) 
     
     
         28 . A method of modulating long term memory formation in a mammal comprising modulating STAUFEN function in said animal. 
     
     
         29 . The method of  claim 28 , wherein long term memory formation is enhanced. 
     
     
         30 . The method of  claim 28 , wherein modulating STAUFEN function comprises administering to said mammal a pharmaceutical agent which modulates STAUFEN function in said mammal, in an amount effective to modulate STAUFEN function in said mammal. 
     
     
         31 . The method of  claim 28 , wherein said mammal is a rodent or a human. 
     
     
         32 . The method of  claim 28  comprising modulating STAUFEN protein expression in said mammal. 
     
     
         33 . The method of  claim 32 , wherein long term memory formation is enhanced. 
     
     
         34 . The method of  claim 32 , wherein modulating STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which modulates STAUFEN protein expression in said mammal, in an amount effective to modulate STAUFEN protein expression. 
     
     
         35 . The method of  claim 32 , wherein said mammal is a rodent or a human. 
     
     
         36 . A method of treating a mammal with a defect in long term memory formation associated with a defect in STAUFEN comprising increasing STAUFEN function in said mammal relative to STAUFEN function in said mammal prior to said treatment. 
     
     
         37 . The method of  claim 36 , wherein increasing STAUFEN function comprises administering to said mammal a pharmaceutical agent which is capable of increasing STAUFEN function in said mammal, in an amount effective to increase STAUFEN function relative to STAUFEN function in said mammal prior to administration of said pharmaceutical agent. 
     
     
         38 . The method of  claim 36 , wherein said mammal is a rodent or a human. 
     
     
         39 . The method of  claim 36  comprising increasing STAUFEN protein expression in said mammal relative to STAUFEN protein expression in said mammal prior to said treatment. 
     
     
         40 . The method of  claim 39 , wherein increasing STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which increases STAUFEN protein expression in said mammal, in an amount effective to increase STAUFEN protein expression relative to STAUFEN protein expression in said mammal prior to administration of said pharmaceutical agent. 
     
     
         41 . The method of  claim 39 , wherein said mammal is a rodent or a human. 
     
     
         42 . The method of  claim 36  comprising administering to said mammal an effective amount of STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein. 
     
     
         43 . The method of  claim 42 , wherein said mammal is a rodent or a human. 
     
     
         44 . The method of  claim 36  comprising administering to said mammal an effective amount of a nucleic acid sequence encoding STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein. 
     
     
         45 . The method of  claim 44 , wherein said mammal is a rodent or a human. 
     
     
         46 . The method of  claim 44 , wherein the nucleic acid sequence is incorporated into a viral vector. 
     
     
         47 . A method of modulating performance by a mammal of a hippocampal-dependent cognitive task comprising modulating STAUFEN function in said mammal. 
     
     
         48 . The method of  claim 47 , wherein performance by a mammal of a hippocampal-dependent cognitive task is enhanced. 
     
     
         49 . The method of  claim 47 , wherein modulating STAUFEN function comprises administering a pharmaceutical agent which modulates STAUFEN function in said mammal, in an amount effective to modulate STAUFEN function in said mammal. 
     
     
         50 . The method of  claim 47 , wherein said mammal is a rodent or a human. 
     
     
         51 . The method of  claim 47  comprising modulating STAUFEN protein expression. 
     
     
         52 . The method of  claim 51 , wherein performance by a mammal of a hippocampal-dependent cognitive task is enhanced. 
     
     
         53 . The method of  claim 51 , wherein modulating STAUFEN protein expression comprises administering a pharmaceutical agent which modulates STAUFEN protein expression in said mammal, in an amount effective to modulate STAUFEN protein expression in said mammal. 
     
     
         54 . The method of  claim 51 , wherein said mammal is a rodent or a human. 
     
     
         55 . A method of treating a mammal with a defect in performance of a hippocampal-dependent cognitive task, said defect in performance associated with a defect in STAUFEN, comprising increasing STAUFEN function in said mammal relative to STAUFEN function in said mammal prior to said treatment, thereby resulting in treatment of said mammal. 
     
     
         56 . The method of  claim 55 , wherein increasing STAUFEN function comprises administering to said mammal a pharmaceutical agent which increases STAUFEN function in said mammal, in an amount effective to increase STAUFEN function relative to STAUFEN function in said mammal prior to administration of said pharmaceutical agent. 
     
     
         57 . The method of  claim 55 , wherein said mammal is a rodent or a human. 
     
     
         58 . The method of  claim 55  comprising increasing STAUFEN protein expression in said mammal relative to STAUFEN protein expression in said mammal prior to said treatment. 
     
     
         59 . The method of  claim 58 , wherein increasing STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which increases STAUFEN protein expression in said mammal, in an amount effective to increase STAUFEN protein expression relative to STAUFEN protein expression in said mammal prior to administration of said pharmaceutical agent. 
     
     
         60 . The method of  claim 58 , wherein said mammal is a rodent or a human. 
     
     
         61 . The method of  claim 55  comprising administering to said mammal an effective amount of STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein. 
     
     
         62 . The method of  claim 61 , wherein said mammal is a rodent or a human. 
     
     
         63 . The method of  claim 55  comprising administering to said mammal an effective amount of a nucleic acid sequence encoding STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein. 
     
     
         64 . The method of  claim 63 , wherein said mammal is a rodent or a human. 
     
     
         65 . The method of  claim 63 , wherein the nucleic acid sequence is incorporated into a viral vector.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.